NeXtGen Biologics Announces Issuance Of A Third New Patent Covering Axolotl-Derived TechnologyGAINESVILLE, Fla., Oct. 07, 2025 (GLOBE NEWSWIRE) -- NeXtGen Biologics announces the issuance of a third U.S. patent, US12311079, on May 27, 2025, as part of its suite of U.S. and foreign patents directed to extracellular matrix components derived from a highly regenerative, non-mammalian species, namely axolotls, a urodele amphibian. In addition to our previous patents1, the most recent patent is directed to a tissue culture system that provides patent coverage for two conditioned media and ECM, and methods of use of these products.
